Eli Lilly: imlunestrant promising in breast cancer

(CercleFinance.com) - Eli Lilly announces the results of the phase 3 trial of imlunestrant in ER+ HER2- advanced breast cancer.


The study showed that as a single agent, imlunestrant reduced the risk of progression or death by 38% in patients with an ESR1 mutation, compared with standard endocrine therapy (SOC ET).

In combination with Verzenio (abemaciclib), it reduced this risk by 43% compared with imlunestrant alone.

The combination showed a median progression-free survival (PFS) of 9.4 months, compared with 5.5 months for imlunestrant alone, with good tolerability and a low rate of serious adverse events.

These results, presented at SABCS 2024 and published in The New England Journal of Medicine, reinforce the potential of imlunestrant as an innovative oral option for ER+ HER2- patients.


Copyright (c) 2024 CercleFinance.com. All rights reserved.